Stockwinners Market Radar for November 23, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:39 EST BridgeBio announces FDA approved Attruby for ATTR-CM patients - BridgeBio Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life. "Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby was designed to mimic a naturally occurring 'rescue mutation' of the TTR gene that targets the root cause of ATTR-CM, destabilization of the native TTR tetramer. Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes," the company stated. BridgeBio submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025. BridgeBio has granted exclusive rights to Bayer to commercialize acoramidis for ATTR-CM in Europe. "With the landmark approval of Attruby, we gain the ability to serve patients with ATTR-CM. I'm grateful to each trial participant, their families, and the physicians, scientists and our team at BridgeBio who made this possible. Our journey is not over as we look to pursue approvals globally, next in Europe, Japan, and Brazil, and to continue exploring the full potential of this treatment. I am thrilled to extend our mission of 'putting patients first' with this third FDA approval in less than 10 years," said Neil Kumar, Ph.D., BridgeBio founder and CEO.

17:56 EST Ranger Energy director Agee sells 61,905 class A shares - In a regulatory filing, Ranger Energy director Brett Agee disclosed the sale of 61,905 class A common shares of the company on November 21 at a price of $16.6726 per share.

17:28 EST Boeing awarded $129.19M Air Force contract action - Boeing was awarded a $129.19M ceiling, undefinitized contract action for the F-15 Japan Super Interceptor program. This contract provides for the Japan Air Self-Defense Force to incorporate engineering change proposals. Work is expected to be completed by January 31, 2030. This contract involves Foreign Military Sales to Japan. FY24 Foreign Military Sales funds in the amount of $44.47M are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:24 EST Lockheed Martin awarded $869.95M Navy contract - Lockheed Martin was awarded a $869.95M fixed-price-incentive-firm- target contract to procure long lead materials, parts, components, and associated support in support of the F-35 Lot 20 production aircraft for the Air Force, Navy, Marine Corps, non-U.S. Department of Defense, or DOD, partners, and Foreign Military Sales, or FMS, customers. Work is expected to be completed May 2031. FY25 aircraft procurement funds in the amount of $197,53M; FY25 aircraft procurement funds in the amount $172.72M; non-U.S. DOD partner funds in the amount of $35.4M; and FMS customer funds in the amount of $464.3M, will be obligated at the time of award, none of which expire at the end of the current fiscal year. This contract was not competed. Naval Air Systems Command is the contracting activity.

17:16 EST IMAC Holdings receives Nasdaq notification of deficiency - IMAC Holdings announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC on November 22, 2024. The Notice indicated that the company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024, as described more fully in the Company's Form 12b-25 Notification of Late Filing filed with the Securities and Exchange Commission on November 15, 2024. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. The company continues to work diligently to file the Form 10-Q as soon as practicable. The Notice has no immediate effect on the listing or trading of the company's common stock on the Nasdaq Capital Market.

16:41 EST Toast director Chapman-Hughes sells 15,285 class A shares - In a regulatory filing, Toast director Susan Chapman-Hughes disclosed the sale of 15,285 class A shares of the company on November 20 at a price of $42.114 per share.

16:31 EST Globus Medical launches ExcelsiusHub navigation system - Globus Medical announced the commercial launch of the ExcelsiusHub navigation system. ExcelsiusHub joins the expansive ecosystem of Excelsius technologies and is designed to elevate the standard for freehand navigation. Freehand navigation provides surgeons with real-time visualization of instrument placement, to reduce the reliance on X-ray imaging during spine surgery. This also facilitates accurate placement of screws and interbody spacer implants and may reduce OR radiation when compared to conventional fluoroscopy. ExcelsiusHub offers advantages over other navigation systems through features designed to enhance the safety and reproducibility of spine navigation such as real-time patient array monitoring, tissue-sparing drills, and registration flexibility. "This launch extends the capabilities and reach of our Excelsius ecosystem," said Dan Scavilla, president and chief executive officer of Globus Medical. "We now have a technology platform that fits a very wide variety of surgeons' and hospitals' needs, with design and footprint suited for both the hospital and ASC setting. We look forward to continuing to support our customers with technology that is designed for less invasive procedures with potentially lower radiation exposure."

16:20 EST Universal Corporation receives noncompliance notice from NYSE - Universal Corporation announced that, as expected, on November 19, it received a notice from the NYSE that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30 with the SEC prior to November 18, the end of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended.

16:17 EST Community Health to sell assets in Florida to Adventist Health for $265M in cash - Community Health announced that certain subsidiaries of the company have entered into a definitive agreement to sell ShorePoint Health Port Charlotte in Port Charlotte, Florida, certain assets of ShorePoint Health Punta Gorda, in Punta Gorda, Florida, and certain ancillary businesses related to such facilities to subsidiaries of Adventist Health System Sunbelt Healthcare for $265M in cash, subject to certain net working capital and other adjustments. Due to the effects of Hurricane Helene and Hurricane Milton, the Punta Gorda hospital has indefinitely suspended inpatient operations. The transaction is expected to close in the first quarter of 2025, subject to regulatory approvals and closing conditions. This transaction is among the additional potential divestitures discussed on the company's third quarter 2024 earnings call and in subsequent public appearances.

16:15 EST Wrap Technologies relocates manufacturing, distribution facility to Virginia - Wrap Technologies announced the relocation of its manufacturing and distribution facility to Virginia, citing Virginia's strategic location as a key factor in its decision. Wrap's new 20,000-square-foot facility has a dedicated professional services division at its core. This division will focus on training, talent development, and customer support to promote integration, large-scale implementation, and ongoing service for law enforcement agencies nationwide.

16:08 EST BridgeBio Pharma trading halted, news pending

16:05 EST Carbon Revolution receives non-compliance letter from Nasdaq - Carbon Revolution announced that the company has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the company's delay in filing its Annual Report on Form 20-F for the fiscal year ended June 30, 2024. The Letter has no immediate effect on the listing or trading of the company's ordinary shares or warrants on Nasdaq. The Letter stated that, under Nasdaq rules, the company has until 60 calendar days after receipt of the Letter, which is January 21, 2025, to submit a plan to regain compliance, and that if a plan is submitted and accepted, Nasdaq could grant the company an exception of up to 180 calendar days from the filing's due date, or until May 14, 2025, to regain compliance. If Nasdaq does not accept the company's plan, then the company will have the opportunity to appeal that decision to a Nasdaq hearings panel. The company continues to work diligently to file its Annual Report as promptly as practical to regain compliance with Nasdaq Listing Rule 5250(c)(1).

14:08 EST GSC's 'S.T.A.L.K.E.R. 2' has sold 1M units so far - GSC Game World said that its new first-person survival game "S.T.A.L.K.E.R. 2: Heart of Chernobyl," which released earlier this week for PC and Xbox Series X/S, has sold 1M units so far, adding that "much more stalkers joined the artifact hunt with Game Pass." The game launched day-and-date on Microsoft's Game Pass subscription service. Reference Link

12:52 EST WHO determines mpox upsurge still constitutes public health emergency - The World Health Organizatiton said that Director-General Dr. Tedros Adhanom Ghebreyesus, agreeing with the advice of the IHR Emergency Committee, has determined that the upsurge of mpox continues to constitute a public health emergency of international concern. The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners. A report of the meeting, including Temporary Recommendations issued by the Director-General to IHR States Parties, will be issued next week. The upsurge of mpox in the Democratic Republic of the Congo and its spread to neighbouring countries was first declared a public health emergency of international concern by the Director-General on 14 August 2024. Shares of Geovax (GOVX) and Emergent Biosolutions (EBS), both of which have mpox-related products, were trading higher after the news. Reference Link

12:00 EST Natural Grocers rises 19.1% - Natural Grocers is up 19.1%, or $6.92 to $43.17.

12:00 EST INNOVATE Corp. rises 24.2% - INNOVATE Corp. is up 24.2%, or $1.17 to $5.99.

12:00 EST Reddit falls -9.2% - Reddit is down -9.2%, or -$14.58 to $143.44.

11:57 EST FDA posts observations from previous Regeneron facility inspection - The FDA posted a summary of observations made from the Agency's inspection of a Regeneron facility in Ireland that was conducted from March 6-10 and 13-14 of 2023 to its website. Reference Link

11:01 EST Petrobras sees ordinary dividends of $45-$55B from 2025 to 2029 - Petrobras laid out its 2025-2029 business plan, which includes paying out ordinary dividends totaling $45-$55B as a "base-case scenario." The company also sees flexibility for extraordinary payments. The stock in morning trading is up 5% to $14.86.

10:49 EST Estee Lauder strength attributed to recent share buys by director - Regulatory filings show that Estee Lauder director Paul Fribourg bought 387,800 shares of the company's stock for a total of $24.9M, for an average price of $64.27 each, from November 13 through 19. Shares of Estee Lauder are up 2% to $68.30 in morning trading, which traders are attributing to a Barron's report highlighting the recent insider buying, contacts tell The Fly. Reference Link

10:30 EST U.S. video game spending rose 10% y/y in October, says Circana - Circana analyst Mat Piscatella said that projected October 2024 total U.S. spending on video game hardware, content and accessories grew 10% when compared to a year ago, to $4.7B. Year-to-date spending is now 1% above a year ago, at $45.4B. The increase was driven primarily by the debut of Activision's (MSFT) "Call of Duty: Black Ops 6" in October, as compared to the launch of "Call of Duty: Modern Warfare III" during the November tracking period a year ago. Video game content spending increased by 12% versus a year ago, reaching $4.2B. Console content was the biggest contributor to the overall gain, with a spending increase of 27% when compared to a year ago, fueled by console digital full game sales. Non-mobile video game subscription spending increased by 16% when compared to a year ago. The release of "Call of Duty: Black Ops 6" as part of Xbox Game Pass was the primary growth driver. "Black Ops 6" was October's best-selling video game, debuting as the #3 best-selling game of 2024 YTD. Over each title's first two weeks in market, full game dollar sales of "Call of Duty: Black Ops 6" were 23% higher than "Call of Duty: Modern Warfare III" a year ago. PlayStation (SONY) platforms accounted for 82% of "Call of Duty: Black Ops 6" total console full game dollar sales volume during the October tracking period. Meanwhile, video game hardware spending dropped 23% in October when compared to a year ago. Switch (NTDOY) dollar sales fell 38% year-on-year during October, while PS5 declined by 20% and Xbox Series showed an 18% decrease. PlayStation 5 was once again the best-selling hardware platform in both unit and dollar sales for the month, with Xbox Series ranking 2nd across both measures. Other top-selling games in the U.S. for the month of October were Bandai Namco's (NCBDY) "Dragon Ball: Sparking! Zero," Konami's (KONMY) "Silent Hill 2," Plaion's "Undisputed," Sega's (SGAMY) "Metaphor: ReFantazio," Electronic Arts' (EA) "Dragon Age: The Veilguard," and Nintendo's (NTDOY) "Super Mario Party Jamboree." Reference Link

10:00 EST Mueller Industries falls -6.2% - Mueller Industries is down -6.2%, or -$5.69 to $86.01.

10:00 EST Cato Corp. falls -20.2% - Cato Corp. is down -20.2%, or -$1.00 to $3.96.

10:00 EST Elastic rises 19.4% - Elastic is up 19.4%, or $18.29 to $112.42.

09:58 EST Invizyne Technologies Inc trading resumes

09:52 EST EchoStar falls 5% to $22.41 after DIRECTV ends deal to buy Dish

09:51 EST Exicure Inc trading resumes

09:49 EST Community Health falls -5.9% - Community Health is down -5.9%, or -22c to $3.53.

09:48 EST Cato Corp. falls -11.9% - Cato Corp. is down -11.9%, or -59c to $4.37.

09:47 EST Gap rises 13.3% - Gap is up 13.3%, or $2.94 to $24.98.

09:46 EST Exicure Inc trading halted, volatility trading pause

09:37 EST Arqit Quantum trading halted, volatility trading pause

09:34 EST Xos receives purchase order from Crown Linen Service for stepvans - Xos announced a purchase order from Crown Linen Service. Crown Linen has ordered two fully electric 22' stepvans, reflecting its commitment to sustainability and reducing its environmental impact.

09:24 EST Terreno Realty sells industrial property in Florida for $20.6M - Terreno Realty sold an industrial property located in Doral, Florida for a sale price of approximately $20.6M. The property consists of one industrial distribution building containing 75,000 square feet on 2.8 acres which is 100% leased to one tenant. The property was purchased by Terreno Realty on July 23, 2012, for approximately $4.2M. The unleveraged internal rate of return generated by the investment was 13.4%.

09:19 EST Amazon to invest additional $4B in Anthropic

09:10 EST UPS to pay $45M penalty for improperly valuing business unit, SEC says - The Securities and Exchange Commission announced settled charges against United Parcel Service Inc. for materially misrepresenting its earnings because it failed to follow generally accepted accounting principles, or GAAP, in valuing one of its worst performing businesses, UPS Freight, a business unit that transported less-than-truckload shipments. Reference Link

09:09 EST Philips announces major step in making radiology expertise accessible - Royal Philips announced a major step forward in making radiology expertise for diagnostic imaging accessible to more patients. The U.S. Food and Drug Administration 510(k) clearance of remote scanning and remote protocol adjustment features on Philips Radiology Operations Command Center, ROCC, means expert radiologists can now assist technologists on-the-spot, by remotely controlling scans or adjusting protocols to acquire high quality images needed for improved diagnostic confidence and patient outcomes.

09:04 EST Citius Pharmaceuticals announces 1-for-25 reverse stock split - Citius Pharmaceuticals announced that it will be executing a reverse stock split of its common stock at a ratio of 1-for-25. Pursuant to the laws of the State of Nevada and subject to prior approval by the company's Board of Directors, Citius Pharma was not required to obtain shareholder approval to effectuate the Reverse Stock Split. The Reverse Stock Split will become effective at 5:00 pm Eastern Time on November 25. The company's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis beginning upon market open on November 26 under the company's existing trading symbol "CTXR" with the new CUSIP number 17322U306. The Reverse Stock Split is intended to increase the per share trading price of Citius Pharma's common stock to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market.

09:02 EST Easterly Government Properties acquires IRS facility in Utah - Easterly Government Properties announced that it has acquired a 100,000 leased square foot facility 100% leased to the General Services Administration, or GSA, for the beneficial use of the Internal Revenue Service, or IRS, located in Ogden, Utah, a geographic hub for the agency. The facility sits on 13 acres and houses operations related to the IRS' tax submission processing and Digital Fraud Department, which was first created within the location.

09:02 EST Global Lights Acquisition, W Straits sign LOI for potential combination - W Straits, an international fintech company, and Global Lights Acquisition Corp. announced the signing of a non-binding letter of intent for a potential business combination. Under the terms of the non-binding letter of intent, W Straits and GLAC would become a combined entity, with W Straits' existing shareholders exchanging their shares in W Straits for equity in the combined public company. W Straits and GLAC expect to finalize a definitive business combination agreement in the coming weeks and plan to announce additional details at that time. Completion of a business combination between W Straits and GLAC is subject to, among other things, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, the satisfaction of the conditions negotiated therein, and approval of the transaction by the board and shareholders of both W Straits and GLAC. There can be no assurance that a definitive agreement will be entered into or that the proposed business combination will be consummated on the terms or timeframe currently contemplated, or at all.

08:48 EST Hudson Acquisition I signs business combination agreement with Aiways Europe - Hudson Acquisition I and Aiways Automobile Europe announced that they have entered into a definitive Business Combination Agreement, pursuant to which, upon the consummation of the transactions contemplated thereby, EUROEV Holdings Limited, a newly formed British Virgin Islands holding company, will acquire the outstanding shares of each of HUDA and Aiways Europe in exchange for newly issued shares of EuroEV, and become listed on the Nasdaq Stock Market. The transaction represents a pre-combination equity valuation of $410 million for Aiways Europe, subject to adjustment. Headquartered in Munich Germany, Aiways Europe is a company focusing on battery electrical vehicles and solutions for the European market. Aiways Europe has built an efficient distribution network, and has sold and serviced approximately 6,000 electrical vehicles in Europe since 2020. Aiways Europe's competitive advantages are characterized by product development pinpointed on European requirements, robust distribution capabilities, cost effective sourcing from its affiliate manufacturer in China, and reduced cycle time on vehicle service update through Over-The-Air capability. In addition to sourcing from its manufacturers in China, Aiways Europe has secured the ability to localize the production of Aiways vehicles in Europe beginning in 2025. In an effort to enlarge its supply base and widen its product portfolio, Aiways Europe has signed MoUs to enter into supply contracts commencing in 2025 with a manufacturer for supplying light vehicles, and with an additional manufacturer for supplying vans and related products. Aiways Europe's CEO, Dr. Alexander Klose-Mozer is anticipated to lead EuroEV after the closing of the Business Combination. The boards of directors or similar governing bodies of Aiways Europe and HUDA have approved the proposed Business Combination, subject to, among other things, approval by Aiways Europe's shareholders and HUDA's stockholders of the proposed Business Combination and satisfaction of the conditions stated in the Business Combination Agreement, including the effectiveness of the proxy statement/prospectus relating to the proposed Business Combination, the receipt of certain regulatory approvals, and approval by The Nasdaq Stock Market to list the securities of EuroEV.

08:39 EST Aptevo Therapeutics highlights potential of portfolio in cancer immunotherapy - Aptevo Therapeutics provided additional details about its oncology pipeline which is poised to potentially address some of the most challenging and aggressive forms of cancer in both blood and solid tumors. As bispecific antibodies gain prominence for their revolutionary therapeutic potential and expanding market opportunities, Aptevo's differentiated platforms and promising clinical results across two clinical programs, together with preclinical assets are demonstrating how bispecifics rationally differentiated for safety and targeted efficacy may impact the future of cancer care. The company plans to add another targeted asset to the pipeline in the near-term and looks forward to providing more detail about the new compound at that time. Aptevo's commitment to transforming cancer therapeutics is exemplified by its development pipeline, which features five bispecific antibodies, two clinical and three preclinical, targeting hematological malignancies and solid tumors. The company's focus on developing highly potent, safe, and versatile therapeutics positions it as a significant player in the expanding field of bispecific antibody based therapies. Lead Candidate Mipletamig for Acute Myeloid Leukemia: Mipletamig, Aptevo's lead bispecific antibody, is currently in a frontline Phase 1b/2 combination trial, RAINIER, following positive results from earlier studies. The Company announced an initial efficacy response earlier this week where the first patient dosed experienced a 90% reduction in leukemic blasts within 30 days of treatment initiation, continuing the efficacy trend seen in prior mipletamig clinical studies. Mipletamig is designed to engage the immune system and directly target AML cells, offering new hope for a patient population with historically poor outcomes. Mipletamig's encouraging clinical performance underscores the potential to transform AML treatment standards, reinforcing Aptevo's innovative approach to tackling blood cancers. Clinical Candidate: ALG.APV-527: ALG.APV-527 is being evaluated in a Phase 1 trial for solid tumors likely to express the tumor antigen 5T4. Tumor types treated to date include breast, colon, pancreatic and non-small cell lung cancer. Positive preliminary data from the study were presented at the European Society of Medical Oncology Congress in September and at the Society for Immunotherapy of Cancer conference earlier in November. These results showed that ALG.APV-527 demonstrated safety and tolerability across all cohorts, nine of 16 evaluable patients achieved stable disease, and biomarker analysis confirmed immune activation in the tumor microenvironment. This drug has the potential to advance treatment in hard-to-treat solid tumors, demonstrating the versatility of Aptevo's technology across a wide range of cancer types. The Company's preclinical candidates represent diverse but complementary approaches to cancer treatment and were designed, like the clinical candidates, with safety, targeted efficacy and combinability in mind. APVO711: Dual immune mechanisms that act as an immune checkpoint blockade plus immune activator where CD40 only functions when both binding domains are engaged APVO603: Broad solid tumor targeting that simultaneously engages two co-stimulatory molecules in the tumor and only functions when both binding domains are engaged APVO442: Precision targeting of prostate cancer antigens with immune engagement driven by CD3 engagement on T cells which are intended to directly kill PSMA-expressing prostate tumor cells.

08:38 EST Halozyme withdraws proposal to acquire Evotec for EUR 11.00 per share in cash - Halozyme Therapeutics (HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, implying a fully diluted equity value of EUR 2B. Helen Torley, president and CEO of Halozyme, shared the following statement: "We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. However, to date, Evotec has been unwilling to engage with us to explore a potential combination and a company spokesperson has publicly commented that its goal is to remain an independent company. As a result, we are withdrawing our proposal to acquire Evotec for EUR 11.00 per share in cash. In the months leading to our proposal, we engaged in extensive external diligence, and we sought to engage with Evotec in a discussion about our vision and the benefits for the combination. Early on, we had informal discussions with a member of the Supervisory Board and communicated our interest in exploring a potential business combination. Subsequently, we sought to earnestly engage Evotec's Chairwoman of the Supervisory Board on Halozyme's vision, and our thoughts as to the many benefits of the transaction; regrettably, our multiple requests to meet were not accepted. Thus, a formal bona fide proposal to the CEO was the only way to convey that our interest in exploring a potential transaction was strong, credible and well informed. It has now become evident that there is no interest at this time on the part of Evotec's Supervisory and Management Boards to engage constructively with Halozyme and explore a potential transaction. We will continue advancing our mission to improve the patient treatment experience and we are confident in Halozyme's future. We believe that we are well-positioned to execute our existing strategy with clear line of sight to 10 approved products with ENHANZE in 2025 and $1 billion of royalty revenue in 2027, continuing to deliver tremendous value for all stakeholders. We reiterate our recently raised 2024 guidance for revenue of $970-$1,020 million and adjusted EBITDA of $595-$625 million, representing significant double-digit growth, as we maintain strong momentum entering 2025."

08:36 EST SeaStar announces two advisory firms recommended vote favor of proposals - SeaStar Medical announces that the two leading independent institutional advisory firms, Institutional Shareholder Services and Glass Lewis, have both recommended that SeaStar Medical stockholders vote in favor of all three proxy proposals discussed in the Company's Definitive Proxy Statement filed on November 4, 2024 in connection with the Company's virtual Special Meeting of Stockholders to be held on November 26, 2024. Proposal One is to ratify, for purposes of maintaining the Company's listing of its common stock on the Nasdaq Stock Market, the issuance of shares of the Company's common stock upon conversion of certain convertible notes and exercise of certain warrants. Proposal Two is to approve an amendment to the Company's Certificate of Incorporation to reduce the number of authorized shares of common stock by 50,000,000 to 450,000,000 shares. Proposal Three is to approve a proposal to adjourn or postpone the Special Meeting to a later date or dates. SeaStar Medical's Board of Directors unanimously supports all three proposals. Voting by at least one-third of SeaStar Medical's common stock outstanding is required to reach a quorum to conduct business at the Special Meeting. Each of the three proposals requires an affirmative vote by a majority of the votes cast in order to pass.

08:34 EST Virpax Pharmaceuticals announces results from Probudur minipig DRF study - Virpax Pharmaceuticals announced results from a minipig dose range finding, or DRF, study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The DRF study was conducted to evaluate the tolerance of Probudur in an incisional wound healing model in minipigs. Probudur was injected locally into the tissue surrounding the incision area. All of the minipigs demonstrated tolerance to Probudur and no adverse effects were noted. The development program for Probudur continues to support the Company's belief that Probudur has the potential to provide both immediate and sustained pain relief at the incisional area. Probudur is being developed to achieve the overall goal of safe and effective pain control during the perioperative period and significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain. In preclinical studies, Probudur has shown long duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five days and in vitro studies demonstrating a slow release of bupivacaine that lasted for up to six days.

08:33 EST Biodexa Pharmaceuticals announces result of general meeting - Biodexa Pharmaceuticals announces that at its General Meeting held earlier, both resolutions put to the Company's shareholders were duly passed.

08:17 EST Nano Dimension urges shareholders to vote for company proposals - Nano Dimension issued a letter to shareholders in connection with the Company's upcoming 2024 Annual General Meeting of Shareholders. The company said, "The letter highlights how Nano's Board and management team have delivered on commitments made to shareholders over the past 12 months, including improving Nano's business performance, executing a disciplined capital allocation plan, and instituting important corporate governance enhancements. After years of attacking Nano and attempting to gain control of the Company, Murchinson STILL has NO plan for value creation and NO executable ideas. With two representatives on the Board already, shareholders must vote FOR Nano's highly qualified nominees to prevent Murchinson from gaining control of half the Nano Board and executing its plans to liquidate the Company. Nano's Board urges shareholders to protect their investment and the Company's future by voting "FOR" ALL of Nano's proposals. Votes must be received by 11:59 p.m. ET on Sunday, December 1, 2024. It is essential that shareholders vote as soon as possible - no matter how many or how few shares they own. Some brokers may have earlier deadlines, so shareholders are encouraged to VOTE TODAY to ensure their vote is counted." Shareholders of record as of the close of business on October 22nd, 2024, are entitled to vote at the Annual Meeting, which will be held on Friday, December 6th, 2024, at 7:00 a.m. ET.

08:08 EST PubMatic, DIGITS agency brings advanced AdTech to local grocery, stores - DIGITS and PubMatic announce their strategic partnership to leverage PubMatic's Convert, a scalable full-funnel commerce media platform, to monetize digital grocery advertising inventory and audiences programmatically with omnichannel, closed-loop reporting. With digital grocery shopping in the United States projected to surpass $200 billion for the first time in 2024, this partnership will empower a robust network of regional grocers, convenience stores and digital commerce platforms to capitalize on this tremendous growth with unprecedented ad tech capabilities.

08:07 EST Rezolve AI strengthens enters partnerships with Google, Microsoft - Rezolve AI (RZLV) has announced back-to-back strategic reseller partnerships with Microsoft (MSFT) and Google (GOOGL), two of the most prominent leaders in generative AI and cloud technology unlocking unparalleled potential to redefine how businesses engage with customers across the entire consumer journey. These partnerships position Rezolve Ai as a comprehensive solution provider in the conversational commerce space, addressing all aspects of the consumer funnel-from initial engagement and personalized recommendations to post-purchase support and loyalty.

08:05 EST WTW increases share repurchase program by $1B - WTW announced that its Board of Directors approved an increase to the existing share repurchase authority in the amount of $1 billion. The $1 billion increase is in addition to the approximately $660 million remaining on the current open-ended repurchase authority. The Company is authorized to repurchase shares, by way of redemption or otherwise, and will consider whether to do so from time to time, based on many factors, including market and economic conditions, applicable legal requirements and other business considerations.

08:04 EST EDAP TMS announces scientific presentation on feasability of Focal One - EDAP TMS announced a scientific presentation which demonstrated the technical feasibility of performing non-thermal histotripsy energy delivery and generating histotripsy lesions in biological tissues ex vivo using the Company's Focal One(R) Robotic HIFU technology. The results from the study were presented on November 19th at the 187th Acoustical Society of America meeting, which is taking place virtually from November 18 - 22, 2024. "The results from this initial technical feasibility study demonstrate EDAP's continued commitment in driving innovation in our core focused ultrasound energy delivery technology," said Ryan Rhodes, Chief Executive Officer of EDAP TMS. "As focal therapy continues to evolve for the treatment of multiple conditions, histotripsy represents an expansion in energy-based therapies that we plan to further invest in and develop as part of our innovation roadmap. This technical milestone, in addition to our clinical development of real-time elastography to enable ablation treatment confirmation, demonstrates our commitment towards remaining the innovation leader in focal therapy."

08:03 EST authID announces integration with Zendesk - authID announced their integration with Zendesk, a leading customer experience company that helps businesses connect with customers across multiple channels. This integration brings authID's best-in-class Proof and Verified products to Zendesk's full suite of customer support solutions, to increase account security and reduce fraud, while providing great service for Zendesk users wherever they may be.

07:56 EST LyondellBasell CFO Michael McMurray to retire, Agustin Izquierdo to succeed - LyondellBasell announced that effective March 1, 2025, Michael McMurray will retire as EVP and CFO and will be succeeded by Agustin Izquierdo, currently the company's SVP, Olefins & Polyolefins Americas & Refining. Until he assumes the role of CFO, Izquierdo will continue to serve in his current role.

07:35 EST Lexicon to eliminate commercial organization, focus on clinical development - Lexicon Pharmaceuticals announced that the company has made the strategic decision to eliminate its commercial operations and rationalize resources across all functions in order to preserve cash and focus its resources on advancing its promising clinical development pipeline. This prioritization of investment is designed to advance the research and development programs that have the greatest potential for value creation and patient impact. This decision follows the receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug Administration regarding the Company's New Drug Application for Zynquista as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease. The letter noted deficiencies with the application that preclude discussion of labeling and/or post-marketing requirements and commitments at this time. Details of the Strategic Restructuring: Complete elimination of the Company's commercial field team and reduction in size of other functions across the organization, including the elimination of all promotional efforts for INPEFA and all planned commercial activities for ZYNQUISTA. A total reduction of approximately 60 percent of employees, effective for most affected employees by December 31st. INPEFA to continue to be manufactured and made available to patients and existing prescribers. An expected reduction of 2025 full year operating costs by $100 million. This amount is in addition to the $40 million in expected 2025 cost savings announced in August as part of a realignment of resources. Reemerging as a Clinical Development-Focused Company: Lexicon will concentrate its resources on the continued research and development of its strong pipeline, including: The Phase 2b PROGRESS study evaluating LX9211 in diabetic peripheral neuropathic pain, with topline data anticipated in Q1 2025. The pivotal Phase 3 SONATA HCM study evaluating sotagliflozin in hypertrophic cardiomyopathy, with enrollment underway. IND-enabling studies of LX9851, a novel, non-incretin oral development candidate in obesity and associated cardiometabolic disorders. Advancing earlier stage opportunities for LX9211 and LX9851 in additional indications. Exploring strategic partnerships to advance and accelerate the value of our pipeline.

07:32 EST Plus Therapeutics to present FORESEE clinical trial summary - CNSide Diagnostics will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform's utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell lung cancer patients with LM. The data will be presented at the 2024 Society for Neuro-Oncology Annual Meeting November 21-24 in Houston, Texas. Key highlights: The FORESEE trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases evaluated, surpassing the predetermined 20% primary endpoint target. CNSide demonstrated enhanced sensitivity in detecting tumor cells vs. CSF cytology in patients with LM. CNSide identified actionable mutations in the CSF, such as HER2 amplification, influencing 24% of therapeutic selection decisions. CNSide exhibited high specificity, with no tumor cells detected in patients without LM. CNSide demonstrated improved Negative Predictive Value in ruling out LM vs. CSF cytology. CNSide revealed HER2 positivity in LM tumors in 60% of breast cancer patients with HER2-negative primary tumors, informing physician treatment strategies. The data will be presented on Sunday, November 24, at 10:15 a.m. CST in a session titled, "CSF Tumor Cell Detection, Quantification and Biomarker assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease," by Priya Kumthekar, M.D., Associate Professor of Neurology and Hematology/Oncology, and Director of Brain Metastases Program at Northwestern, University, Chicago, Illinois.

07:12 EST Ecarx showcases Skyland Pro ADAS solution at AutoSens China 2024 - ECARX recently showcased the advanced capabilities of its Skyland Pro ADAS solution at AutoSens China 2024, demonstrating how it empowers automakers with high-performance, cost-effective intelligent driving solutions. A key platform for collaboration among automotive professionals, AutoSens China 2024 attracted prominent companies and experts from across the intelligent driving ecosystem, including Volkswagen, BMW-Brilliance and NIO. ECARX continues to enhance the performance of Skyland Pro while replicating and scaling it across various brands and models. With a clear roadmap for future ADAS solutions, ECARX is committed to delivering advanced and reliable intelligent driving solutions to support automakers globally in their drive towards the future of mobility.

07:11 EST Green Thumb expands national retail footprint to over 100 stores nationwide - RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries, announced the opening of its landmark 100th retail location, with RISE Dispensary Carson City on US HWY 50 on November 23, located at 3060 US-50 E, Carson City, NV 89701. In addition, the Company announced the opening of its 101st retail location with RISE Dispensary Brooklyn Park on November 23, located at 8016 Brooklyn Blvd., Brooklyn Park, MN 55445. The two new locations represent the 11th and 8th dispensaries to open in Nevada and Minnesota, respectively.

07:08 EST Barrick Gold updates MRE for Fourmile Project in Nevada - Barrick Gold updated its mineral resource estimate for its wholly-owned Fourmile project in Nevada, resulting in a 192% increase in indicated resources, a 137% increase in inferred resources and a 35% increase in grade relative to Barrick's 2023 year-end mineral resource estimate. The increases reflect the addition of 25 new drill holes to the 2023 mineral resource estimate across the southernmost portion of the orebody, immediately adjacent to the Goldrush project at Cortez which is part of the Nevada Gold Mines joint venture. Speaking at Barrick's Investor Day in New York, president and chief executive Mark Bristow said that the Fourmile project was a truly world-class asset and could be compared to the original Goldstrike deposit, the foundational asset of Barrick which is now part of NGM's Carlin. "Our strategy of investing in organic growth through exploration and mineral resource management has set us apart from the industry. We believe in creating real value through discovery and development rather than relying on an increase in the gold price to justify high-premium mergers and acquisitions," he said. "Since the formation of the NGM joint venture in 2019, we have added more than 19Moz of proven and probable mineral reserves to the life of mine plan on a 100% basis. This does not yet reflect the additional exploration upside that we see today, including Greater Leeville and Hanson in Cortez Underground," said Bristow. Mineral resource management and evaluation executive Simon Bottoms added that the updated mineral resource estimate for Fourmile only covers approximately one-third of the overall orebody as defined by drilling to date. "To illustrate the potential value that a truly world-class orebody like Fourmile has, we have completed a preliminary economic assessment using conservative mining rates and costs, all of which draw directly from the current Goldrush mine plan. The results highlight the potential for annual operating cash flows resulting from Fourmile to be more than 70% higher than the already world-class Goldrush project. For the next stage of the project, we plan to start a three-year prefeasibility study in 2025, which will not only continue to define substantial resources and reserves across the entire orebody from surface drilling, while the northern Bullion Hill access is permitted and developed, but will also undertake pilot autoclave and roaster test work," Bottoms said.

07:07 EST NewGenIvf Group receives Nasdaq delisting notice, plans to appeal - NewGenIvf Group announced that on November 21 2024, it received written notice from The Nasdaq Stock Market that its securities are subject to delisting due to non-compliance with two Nasdaq Listing Rules. The Company has filed to appeal the delisting determination and plans to leverage several strategic actions to regain compliance with Nasdaq's listing requirements. Following receipt of the Delisting Notice, the Company will formally request a hearing to appeal the delisting determination. This request will stay any further action by Nasdaq at least pending completion of the hearing and the expiration of any extension that may be granted by the Panel to the Company following the hearing

07:04 EST Poet Technologies intends to voluntarily delist from TSXV - POET Technologies announced that the Company's board of directors has approved the voluntary delisting of POET's common shares from the TSX Venture Exchange. The Company intends to submit an application to the TSXV to complete such Delisting in due course. Upon submission of the Company's application, the Delisting will be subject to the approval of the TSXV and the satisfaction of all necessary conditions. POET's Shares will continue to be listed on the Nasdaq Capital Market under the symbol "POET" and shareholders will be able to continue to trade their Shares through the Nasdaq. Trading on the Nasdaq represents the vast majority of the Company's trading volume. Given the low trading volume on the TSXV the Company has determined, after due consideration, that maintaining the TSXV listing does not form part of the Company's go-forward capital markets strategy. The Company is not required to seek security holder approval for the Delisting since an alternative market for POET's Shares exists on the Nasdaq. POET will remain a "reporting issuer" in Canada and will continue to provide regular comprehensive disclosure pursuant to applicable Canadian securities laws. Additional information regarding the Company's Delisting application will be disseminated in due course.

07:00 EST Cato Corp. suspends regular quarterly dividend - In light of the current economic conditions and current sales trends the Board of Directors of The Cato Corporation suspended the regular quarterly dividend.

06:49 EST Tapestry announces $2B Accelerated Share Repurchase program - Tapestry announced that it entered into Accelerated Share Repurchase agreements with Bank of America N.A. and Morgan Stanley & Co. to repurchase $2B shares of Tapestry common stock. The ASRs will be completed under the company's recently expanded $2.8B share repurchase authorization. With the ASRs, the company expects to return over 100% of its free cash flow in Fiscal 2025 to shareholders through dividends and share repurchases. Under the ASR agreements, Tapestry will pay $2B to the Dealers and expects to receive an initial delivery of 28.4M shares of Tapestry common stock on November 26, representing approximately 80% of the expected shares to be repurchased under the ASR agreements. The final settlement of the transactions under the ASR agreements is expected to occur no later than the first quarter of Fiscal 2026 ending September 27, 2025.

06:37 EST GSK announces Japan's MHLW approved application to extend indication of Arexvy - GSK announced that Japan's Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include adults aged 50-59 at increased risk. Since September 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over for the prevention of RSV disease. Tony Wood, Chief Scientific Officer at GSK, said: "This approval reflects our ambition to protect people at increased risk from the severe consequences of RSV infection. Adults aged 50-59 with certain underlying medical conditions can face debilitating consequences from RSV, so we are pleased to offer those in Japan a vaccine for the first time." This regulatory expansion was supported by results from a global phase III trial that showed non-inferior immunogenicity in adults aged 50-59 at increased risk of RSV lower respiratory tract disease compared to those aged 60 and older. Safety and reactogenicity in the 50-59 at increased risk population were consistent with results from the initial phase III program in adults aged 60 and older.

06:10 EST Global Blue increases share buy-back program to $15M from $10M - Global Blue's CEO, Jacques Stern, commented: "In addition, and in light of the solid improvement in free cash flow generation, we have increased our share buy-back program from $10 million to $15 million and extended the program to November 30, 2025."

06:04 EST Beneficient adds $35M of equity to balance sheet - Beneficient announces that its subsidiary, Beneficient Company Holdings, consummated a previously announced transaction pursuant to which approximately $35M of its preferred equity was redesignated as non-redeemable, resulting in the addition of approximately $35M of permanent equity on its balance sheet. As a result of the transaction, the company believes it now has stockholders' equity of at least $2.5M, the amount required to regain compliance with Nasdaq's Minimum Stockholders' Equity Requirement. The company's compliance with Nasdaq's Minimum Stockholders' Equity Requirement is subject to Nasdaq's final determination.

06:02 EST Scilex receives Nasdaq notice of non-compliance - Scilex reported that it received a notice on November 21 from the Listing Qualifications Department of The Nasdaq Stock Market advising the company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30 in a timely manner. In response to the Notice, the company intends to file the Q3 Form 10-Q as soon as possible in order to regain compliance with the Listing Rule. However, if the company does not submit the Q3 Form 10-Q by January 20, 2025, the company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the company will take to promptly file the Q3 Form 10-Q.

05:37 EST Hutchmed to receive milestone payment following Takeda launch of Fruzaqla - Hutchmed (HCM) announced that it will receive a milestone payment following the pricing approval and launch of Fruzaqla 1mg/5mg capsules in Japan by its partner Takeda (TAK) for patients with previously treated metastatic colorectal cancer, or CRC. This follows approval for the manufacturing and marketing of Fruzaqla by the Japanese Ministry of Health, Labour and Welfare. Fruzaqla is the first novel oral targeted therapy in Japan to be approved for metastatic CRC, regardless of biomarker status, in over a decade. Fruzaqla is indicated for the treatment of advanced or recurrent colorectal cancer that is neither curable nor resectable, and that has progressed after chemotherapy. The launch of Fruzaqla in Japan follows its approval in September, primarily based on results from the Phase III FRESCO-2 trial conducted in the U.S., Europe, Japan and Australia. Data from FRESCO-2 were published in The Lancet in June 2023. Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau, and markets under the Fruzaqla brand name. It received approval in the U.S. in November 2023, in the EU in June, in Switzerland in August, in Canada, Japan and the United Kingdom in September and in Argentina, Australia and Singapore in October. Regulatory applications are progressing in many other jurisdictions.

05:22 EST PepsiCo to acquire remaining 50% interest of Sabra and Obela, terms undisclosed - PepsiCo announced its agreement to acquire the remaining 50% interest in Sabra and PepsiCo-Strauss Fresh Dips & Spreads International, or Obela, and become the sole owner of these companies, which make Sabra and Obela products. Sabra and Obela are currently 50/50 joint ventures that had been formed between PepsiCo and Strauss Group to manufacture, distribute, and sell refrigerated dips and spreads. The Sabra joint venture is based in New York and operates in the U.S. and Canada. The Obela joint venture is based in Geneva and operates in Australia, New Zealand and Mexico. PepsiCo has focused on the fresh dips category for over 15 years, forming Sabra and Obela as 50/50 joint ventures with the Strauss Group in 2008 and 2012, respectively. Sabra has nearly $400M in retail sales in the U.S. The transactions are subject to customary closing conditions and are expected to close by the end of 2024. Additional terms of the acquisitions were not disclosed.